Financial Performance - In the first half of 2024, the company achieved total operating revenue of 799,304.35 million yuan, a decrease of 10.82% compared to the same period last year [2] - The net profit attributable to shareholders was 27,668.29 million yuan, an increase of 161.86% year-on-year [2] - The feed business sold 134.94 million tons, a year-on-year increase of 7.6%, but sales revenue decreased by 5.63% due to price fluctuations in raw materials [2][3] Business Segment Analysis - The pig farming business had a total of 140.14 million pigs slaughtered, an increase compared to last year [2] - The animal vaccine business maintained stable sales and profitability, with revenue of 50,000.14 million yuan, a year-on-year increase of 12.04% [3] - The plant protein and corn storage businesses saw a decline in revenue due to a downward trend in raw material prices [3] Cost Management - The complete cost of pig farming in Q2 was 15.15 yuan/kg, which decreased to 14.75 yuan/kg in July [3] - The company plans to improve production efficiency and management levels to further reduce costs [4] Future Outlook - The company is focusing on upgrading hardware facilities for epidemic prevention, particularly in Henan and Gansu regions [4] - The animal vaccine business is expected to see improved gross margins as market conditions for pig farming become more favorable in the second half of the year [4]
天康生物(002100) - 天康生物投资者关系管理信息